All together these data are in line with the notion that c-Myc is a downstream target of MEK/ERK pathway and suggest that aberrant growth of different tumor cell lines can be halted by targeting c-Myc following MEK/ERK inhibition. The gene discussed is MAP2K7; the disease is neoplasm.